ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | Finanzwire

Basculer en Français

9473	Companies
185423	Keywords
117773	Articles
99292	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

BRIEF

published on 10/15/2025 at 19:05, 1 month 20 days ago

OSE Immunotherapeutics Reports 2025 First Half Financial Results

Revenue Decline OSE Immunotherapeutics Cash Runway R&D Expenses 2025 Financial Results
PRESS RELEASE

published on 10/15/2025 at 19:00, 1 month 20 days ago

OSE Immunotherapeutics Reports First Half 2025 Financial Results
OSE Immunotherapeutics reports first half 2025 financial results with operating loss of 15.8 million euros and net loss of 15.1 million euros. Research and development expenses increased 6.7%

Financial Results Net Loss Operating Loss OSE Immunotherapeutics Research And Development Expenses
BRIEF

published on 10/09/2025 at 16:02, 1 month 26 days ago

OSE Immunotherapeutics: End of a concerted action between shareholders

Shareholders Threshold Crossing OSE Immunotherapeutics Capital And Voting Rights Terminated Agreement
BRIEF

published on 09/30/2025 at 19:35, 2 months 4 days ago

OSE Immunotherapeutics: Reorganization of the Board of Directors

Board Of Directors Biotechnology Immunotherapy OSE Immunotherapeutics Markus Cappel
PRESS RELEASE

published on 09/30/2025 at 19:30, 2 months 4 days ago

Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors
OSE Immunotherapeutics renews Board of Directors and elects Dr. Markus Cappel as Chairman. Shareholders vote on key appointments

Board Of Directors Shareholders General Meeting OSE Immunotherapeutics Dr. Markus Cappel
BRIEF

published on 09/26/2025 at 07:05, 2 months 9 days ago

Strategic Partnership for Innovation in Immunotherapy

Strategic Partnership Oncology Industrial Support Immunotherapy Innovation Collaborative Research
PRESS RELEASE

published on 09/26/2025 at 07:00, 2 months 9 days ago

OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy
OSE Immunotherapeutics, Inserm Transfert, and Nantes University form a strategic partnership to advance immunotherapy for oncology, inflammation, and autoimmunity. The collaboration combines academic research and industrial expertise

Innovation Partnership Oncology Collaboration Immunotherapy
BRIEF

published on 09/24/2025 at 08:05, 2 months 11 days ago

OSE Immunotherapeutics Corrects Voting Rights Error Before General Meeting

Voting Rights Shareholder Meeting Accusations Material Error Proxy Firms
PRESS RELEASE

published on 09/24/2025 at 08:00, 2 months 11 days ago

Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital
OSE Immunotherapeutics corrects material error in total number of shares and voting rights, refutes accusations, and provides clarity on shareholder agreements and proxy advisory recommendations

Correction Proxy Advisory Shareholder Agreements OSE Immunotherapeutics Material Error
BRIEF

published on 09/23/2025 at 22:35, 2 months 11 days ago

OSE Immunotherapeutics Responds to Court Decision

General Meeting Shareholder Rights OSE Immunotherapeutics Nantes Commercial Court Voting Rights Error

1 2 ... 4

Accesswire

Published on 12/05/2025 at 02:35, 7 hours 26 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 7 hours 31 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 9 hours 1 minute ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 10 hours 56 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 11 hours 1 minute ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 09:40, 20 minutes ago

Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 30 minutes ago

REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 55 minutes ago

Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 09:00, 1 hour ago

Original-Research: DEMIRE AG (von NuWays AG): BUY
Published on 12/05/2025 at 09:00, 1 hour ago

SPECTRIS PLC - Removal

Les Echos

Published on 12/05/2025 at 08:45, 1 hour 16 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 16 hours 1 minute ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 16 hours 16 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 16 hours 16 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 3 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE